[Home] [About us] [Diseases ] [Research] [Products] [MICROS] [Clinical] [Collaboration] [News] [Contact]

Innovative treatment for unmet needs in neurological diseases

Neurons Brain Neurons Brain biochemicals MICROS Infusion System Human brain signals Alzheimer patient Famous People with Alzheimer

NeuroActiva, Inc.

NeuroActiva, Inc. is a clinical stage bio-pharmaceutical company committed to the discovery and development of new drugs to treat neurological diseases for which there is significant unmet medical need.

Read More

ABOUT US

NeuroActiva, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of new drugs to treat Alzheimer’s disease and other neurological disorders

DISEASES

NeuroActiva focuses on unmet medical needs: Alzheimer's disease, Parkinson's disease, Edema, Multiple Sclerosis , traumatic brain injury, stroke, and brain cancer.

RESEARCH

Our core research areas focuses on Alzheimer's disease and Multiple Sclerosis. In addition , we are doing clinical research on Parkinson's disease, traumatic brain injury, stroke, and other neurological diseases.

CLINICAL

Our new platform of neuroprotective and neurogenesis drugs for treatment of Alzheimer include: Traneurocin (NA-831) is in Phase 1 clinical trial (late 2017 - 2018) and Vineurocin (NA-704) will be in Phase 2 in 2018.

.

PRODUCTS

Vineurocin (NA-704) and NA-831 (Traneurocin) are novel neuroprotective and neurogensis drug candidates for the treatment of Alzheimer's disease and other neurological disorders.

MICROS Infuser

The MICROS is a FDA approved intravenous drug delivery system for injectable drugs, including Traneurocin for treatment of neurological diseases in homecare settings.

NeuroActiva focuses on developing of treatment of Alzheimer's disease:

  • Alzheimer's disease

    Alzheimer's Disease

    Alzheimer's disease is the only cause of death in the top 10 in America that cannot be prevented, cured or slowed. Alzheimer is the 6th leading cause of death in the USA.

  • Research

    Research

    NeuroActiva research focuses on the neuroprotection and regeneration of cells and tissue with its ability to repair damage caused by disease, trauma or age.

  • Clinical

    Clinical

    Vineurocin (NA-704) and Traneurocin (NA-831) have been developed for the treatment of Alzheimer's disease and other neurological disorders. NA-831 is in Phase 1 (late 2017-2018) and NA-704 is in Phase 2 clinical trial (2018)

  • Traneurocin

    Vineurocin and Traneurocin

    Vineurocin and Traneurocin protect damaged neurons and stimulates regeneration of neurons, outgrowth of electrically active fibres, restoration of neuronal function, a major clinical feature of both Alzheimer's disease.

  • MICROS Infusion System

    MICROS Infusion System

    The MICROS is a FDA approved disposable infusion system for intravenous administration of injectable drugs, including Traneurocin for treatment of neurological diseases.